nasopharyngeal carcinoma
Conditions
Interventions
Case series:individualized 3D-image-guided brachytherapy plan after the intensity-modulated radiation
Sponsors
Jiangxi Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. WHO II/III patients with initial diagnosis of nasopharyngeal cancer; 2. The clinical phase is T1-2N0-3M0(I-IVa, UICC/AJCC 8th edition), and T2 phase pharynx violations = 1.5 cm; 3. Receive strong radiation therapy and post-installation radiotherapy; 4. ECOG PS 0-2 points; 5. Aged between 18 and 70 years; 6. Male or non-pregnant or lactating female; 7) Hematology examination: white blood cells >4×10^9/L, neutrophils >2×10^9/L, hemoglobin >90g/L, platelet>100×10^9/L; 8. Liver function: ALT, AST60 ml/min; 10. The patient has signed an informed consent form.
Exclusion criteria
Exclusion criteria: 1. WHO pathological classification is keratinized squamous carcinoma or basal cell-like carcinoma; 2. palliative care; 3. History of other malignant neoplasms(basal cell carcinoma of the skin / squamous carcinoma, except cervical carcinoma in situ); 4. Pregnant or lactating women(women of childbearing age are considering pregnancy tests and patients are required to use effective contraception during treatment); 5. Past history of radiotherapy(except for non-melanoma of the skin outside the target area of the planned exposure); 6. Chemotherapy or surgery has been performed on primary focal or lymph nodes(except for diagnostic operations); 7. Any serious disease that may pose a risk to the test or affect the compliance of the test, such as unstable heart disease, kidney disease, chronic hepatitis, diabetes with poor blood sugar control that requires treatment(fasting blood sugar > 1.5 × ULN) and emotional illness; 8. Past history of radiation therapy of the head and neck; 9. Past history of cancer.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Local free-recurrence period; | — |
Secondary
| Measure | Time frame |
|---|---|
| Acute reactions and late adverse complications;overall survival rate; | — |
Countries
China
Contacts
Public ContactTang Yiqiang
Jiangxi Cancer Hospital
Outcome results
None listed